Responder Analysis Evaluating the Long-term Treatment of Budesonide/Formoterol Pressurized Metered-Dose Inhaler (BUD/FM pMDI) in Patients With Moderate to Severe Asthma With Versus Without Fixed Airflow Obstruction (FAO)

CHEST Journal ◽  
2013 ◽  
Vol 144 (4) ◽  
pp. 79A ◽  
Author(s):  
Donald Tashkin ◽  
Bradley Chipps ◽  
Randall Brown ◽  
Tom Uryniak ◽  
Frank Trudo
Keyword(s):  
Severe Asthma ◽  
Airflow Obstruction ◽  
Term Treatment ◽  
Dose Inhaler ◽  
Metered Dose Inhaler ◽  
Responder Analysis ◽  
Long Term Treatment ◽  
Metered Dose ◽  
Fixed Airflow Obstruction

scholarly journals A Novel, Portable MESH Nebulizer—An Alternative to Metered Dose Inhaler: Efficacy and Usability in Preschool Wheezers

2020 ◽  
Vol 8 ◽  
Author(s):  
Nicola Ullmann ◽  
Antonio Di Marco ◽  
Fabiana Columbu ◽  
Valentina Negro ◽  
Maria Beatrice Chiarini Testa ◽  
...  
Keyword(s):  
Similar Efficacy ◽  
Term Treatment ◽  
Preschool Age ◽  
Dose Inhaler ◽  
Metered Dose Inhaler ◽  
Long Term Treatment ◽  
Significant Difference ◽  
Metered Dose

Introduction and Objectives: Wheezing episodes are the first causes of doctor's consultation in preschool age. Treatment is usually administered with a metered dose inhaler (MDI) spacer. At variance, many parents and doctors prefer to use a compressor nebulizer, which cannot be easily carried. The study is aimed at testing whether a pocket mesh nebulizer has similar efficacy and acceptability than a standard MDI device.Materials and Methods: The IPAC study was a randomized, controlled, non-inferiority trial (number: 1616/2018, Ospedale Pediatrico Bambino Gesu'—IRCCS). The study had two arms: cases, using MicroAIR U100, and controls, using MDI+spacer device. Both devices were adopted for long-term treatment and for exacerbations. Follow-up was organized with clinical visits and a daily e-diary connected to an application for mobile phone.Results: One hundred patients were enrolled. The frequency of asthmatic symptoms showed a non-inferiority for MicroAIR U100 group vs. MDI. Accordingly, no significant difference was found in the average % of days with cough, wheezing, breathlessness after exercise, days lost at school, and not-programmed visits. Considering only patients with >1 day with symptoms, no significant sdifferences were found in the number of exacerbations nor in the cumulative days with symptoms. The acceptance and usability of both devices have been favorable. However, the MDI+AeroChamber® device showed better acceptability.Conclusions: Our study shows that MicroAIR U-100, a mesh nebulizer, has similar clinical efficacy but lower acceptance and usability than an MDI plus Aerochamber® in delivering therapy in preschool wheezers. Therefore, MicroAIR U-100 might be a valuable second choice, when the delivery of medication with an MDI plus Aerochamber® is not accepted, or wrongly used by the parents.

Sign in / Sign up

Export Citation Format

Share Document